文献速递前列腺癌

68Ga-前列腺特异性膜抗原(PSMA)正电子发射断层扫描/计算机断层扫描(PET/CT)对根治性治疗后前列腺特异性抗原(PSA)升高的前列腺癌患者的临床影响:多学科方法的初步分析

Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach.
PubMed 文献 · BJU Int · 2017-01-04

本研究评估68Ga-PSMA PET/CT对根治性治疗后PSA升高的前列腺癌患者临床管理的影响。131例连续患者接受68Ga-PSMA PET/CT,98/131(75%)检出可疑病灶,99/131(76%)的治疗策略发生改变。作者认为该检查在相当比例患者中可改变治疗策略,但需更大规模前瞻性试验验证。

要点

  • 68Ga-PSMA PET/CT在131例PSA升高患者中检出至少一个可疑病灶的比例为75%(98/131)。
  • 68Ga-PSMA PET/CT对76%(99/131)患者的后续管理产生影响,主要修改包括继续监测、内分泌治疗、立体定向放疗等。
  • 作者认为该检查可临床有用,但需更大规模前瞻性试验验证。

核心结论

  • 作者初步经验提示,对根治性治疗后PSA升高的前列腺癌患者行68Ga-PSMA PET/CT可临床有用,因其在显著比例患者中改变治疗策略,但需更大规模前瞻性试验验证。

研究设计与样本

  • 单中心连续纳入131例根治性治疗后PSA升高的前列腺癌患者,转诊行68Ga-PSMA PET/CT。
  • 注射2 MBq/kg的68Ga-(HBED-CC)-PSMA配体后1小时采集图像,由两名经验丰富的核医学专家判读。
  • 多学科肿瘤委员会(MOC)根据检查结果报告治疗策略;若检查导致治疗策略较PSMA显像前MOC决策发生修改,则视为对临床管理有积极影响。

主要发现

  • 11/131(8%)患者为根治性前列腺切除术后持续性PSA,120/131(92%)因手术、放疗或两者后生化复发转诊。
  • 检查时中位(四分位距)PSA水平为2.2(0.72-6.7)ng/mL。
  • 68Ga-PSMA PET/CT在98/131(75%)患者中检出至少一个可疑前列腺癌病灶。
  • 99/131(76%)患者的后续管理受到影响。
  • 所有患者完成检查,无不良反应。

关键数值与推荐

  • 主要治疗策略修改包括继续监测(暂缓内分泌治疗)、内分泌治疗、立体定向放疗、挽救性放疗、挽救性淋巴结清扫或挽救性局部治疗(前列腺切除术、高强度聚焦超声)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为初步分析,作者结论中写明需更大规模前瞻性试验验证当前发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of a novel molecular imaging technique, 68 Ga-(HBED-CC)-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT), in the clinical management of patients with prostate cancer with rising prostate-specific antigen (PSA) after treatment with curative intent. PATIENTS AND METHODS: In all, 131 consecutive patients were referred to our centre for a 68 Ga-PSMA PET/CT in the setting of recurring prostate cancer. Of these patients, 11/131(8%) presented with persistent PSA after radical prostatectomy, while 120/131 (92%) were referred for biochemical recurrence after surgery, radiotherapy or both. The images where taken 1 h after injection of 2 MBq/kg of the 68 Ga-(HBED-CC)-PSMA ligand. All examinations were interpreted by two experienced nuclear medicine specialists. Using the results of the examination, a multidisciplinary oncology committee (MOC) reported on the treatment strategy. A positive impact on clinical management was considered if the examination determined a modification in the treatment strategy compared to the MOC decision before PSMA imaging. RESULTS: All patients completed the examination with no adverse reactions. The median (interquartile range) PSA level at the time of the examination was 2.2 (0.72-6.7) ng/mL. Overall, 68 Ga-PSMA PET/CT detected at least one lesion suspicious for prostate cancer in 98/131 (75%) patients. There was an impact on subsequent management in 99/131 patients (76%). The main modifications included continuing surveillance (withholding hormonal therapy), hormonal manipulations, stereotaxic radiotherapy, salvage radiotherapy, salvage node dissection or salvage local treatment (prostatectomy, high-intensity focussed ultrasound). CONCLUSION: Our preliminary experience suggests that performing 68 Ga-PSMA PET/CT in patients with prostate cancer with rising PSA after treatment with curative intent can be clinically useful as it changes the treatment strategy in a significant proportion of patients. However, larger prospective trials are needed to validate our present findings.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Albisinni S, Artigas C, Aoun F, et al. Clinical impact of 68 Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: preliminary analysis of a multidisciplinary approach. BJU Int. 2017. PMID: 27981732. doi:10.1111/bju.13739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。